CRISPR Therapeutics AG (NASDAQ:CRSP) and Adial Pharmaceuticals Inc. (NASDAQ:ADIL), both competing one another are Biotechnology companies. We will compare their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||60||0.00||34.37M||-0.46||0.00|
|Adial Pharmaceuticals Inc.||2||0.00||6.54M||-0.89||0.00|
We can see in table 1 the earnings per share (EPS), gross revenue and valuation of CRISPR Therapeutics AG and Adial Pharmaceuticals Inc.
Table 2 provides the net margins, return on assets and return on equity of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||57,235,636.97%||-2.6%||-2%|
|Adial Pharmaceuticals Inc.||419,230,769.23%||-89.3%||-84.5%|
CRISPR Therapeutics AG has a Current Ratio of 8.3 and a Quick Ratio of 8.3. Competitively, Adial Pharmaceuticals Inc.’s Current Ratio is 12.2 and has 12.2 Quick Ratio. Adial Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than CRISPR Therapeutics AG.
The Ratings and Recommendations for CRISPR Therapeutics AG and Adial Pharmaceuticals Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
|Adial Pharmaceuticals Inc.||0||0||0||0.00|
CRISPR Therapeutics AG has an average price target of $72, and a 8.45% upside potential.
Institutional & Insider Ownership
Institutional investors owned 46.8% of CRISPR Therapeutics AG shares and 15.2% of Adial Pharmaceuticals Inc. shares. About 0.4% of CRISPR Therapeutics AG’s share are owned by insiders. Insiders Competitively, owned 3.4% of Adial Pharmaceuticals Inc. shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
|Adial Pharmaceuticals Inc.||4.14%||-5.63%||-1.31%||-25.98%||-49.67%||-70.51%|
For the past year CRISPR Therapeutics AG had bullish trend while Adial Pharmaceuticals Inc. had bearish trend.
CRISPR Therapeutics AG beats Adial Pharmaceuticals Inc. on 7 of the 10 factors.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.